Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Public ClinicalTrials.gov record NCT00742404. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients With Newly Diagnosed Multiple Myeloma (MM)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving bortezomib together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving doxorubicin hydrochloride liposome together with bortezomib and dexamethasone works in treating patients with newly diagnosed multiple myeloma.
Study identification
- NCT ID
- NCT00742404
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 35 participants
Conditions and interventions
Conditions
Interventions
- bortezomib Drug
- dexamethasone Drug
- pegylated liposomal doxorubicin hydrochloride Drug
- protein analysis Genetic
- immunologic technique Other
Drug · Genetic · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2008
- Primary completion
- Jun 30, 2010
- Completion
- Not listed
- Last update posted
- Dec 17, 2013
Started 2008
United States locations
- U.S. sites
- 12
- U.S. states
- 5
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Clinical Research Center, Incorporated | Tucson | Arizona | 85712 | — |
| Comprehensive Blood and Cancer Center | Bakersfield | California | 93309-0633 | — |
| San Diego Pacific Oncology and Hematology Associates, Incorporated - Escondido | Escondido | California | 92025 | — |
| Loma Linda University Cancer Institute at Loma Linda University Medical Center | Loma Linda | California | 92354 | — |
| Oncology Care Medical Associates - San Gabriel | Los Angeles | California | 90057 | — |
| Desert Cancer Care | Rancho Mirage | California | 92270 | — |
| Sutter Cancer Center at Roseville Medical Center | Roseville | California | 95661 | — |
| Santa Barbara Hematology Oncology Medical Group at Cancer Center of Santa Barbara | Santa Barbara | California | 93105 | — |
| James R. Berenson MD, Incorporated | West Hollywood | California | 90069 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| New York Medical College | Valhalla | New York | 10595 | — |
| Charleston Hematology Oncology Associates, PA | Charleston | South Carolina | 29403 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00742404, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 17, 2013 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00742404 live on ClinicalTrials.gov.